Detalles de la búsqueda
1.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer;
128(2): 255-265, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36482193
2.
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Br J Cancer;
127(1): 92-101, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35568736
3.
Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare Neoplasm.
Int J Gynecol Pathol;
40(2): 190-195, 2021 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31985580
4.
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.
Br J Cancer;
123(4): 525-533, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32523090
5.
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
Oncologist;
25(1): e109-e119, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31575788
6.
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Int J Gynecol Cancer;
29(9): 1396-1404, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31685558
7.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Br J Cancer;
114(7): 723-30, 2016 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-27002934
8.
The development of PARP inhibitors in ovarian cancer: from bench to bedside.
Br J Cancer;
113 Suppl 1: S3-9, 2015 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26669452
9.
Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
Clin Cancer Res;
30(11): 2461-2474, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38536067
10.
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Clin Cancer Res;
30(1): 50-62, 2024 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37939124
11.
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Invest New Drugs;
31(3): 623-30, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22688291
12.
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response.
Cells;
11(15)2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35954206
13.
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.
Cancers (Basel);
14(22)2022 Nov 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36428653
14.
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
Clin Lung Cancer;
23(7): e415-e427, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35729005
15.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Br J Cancer;
114(12): e21, 2016 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27228289
16.
Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma.
Cancers (Basel);
14(1)2021 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35008180
17.
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
Cancers (Basel);
13(6)2021 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33804647
18.
Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer.
J Clin Pathol;
74(7): 469-474, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33214200
19.
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Cancer Chemother Pharmacol;
88(2): 259-270, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909097
20.
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Cancer Discov;
11(1): 80-91, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32988960